Circulating microRNAs in Patients with Shiga-Toxin-Producing E. coli O104:H4 Induced Hemolytic Uremic Syndrome
Open Access
- 11 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10), e47215
- https://doi.org/10.1371/journal.pone.0047215
Abstract
In early May 2011, an outbreak of hemorrhagic colitis associated with hemolytic–uremic syndrome (HUS) first developed in Northern Germany and spread to 15 other countries in Europe. The outbreak-strain O104:H4, which combined virulence factors of typical enteroaggregative and Shiga-Toxin–producing E. coli was associated with an unusual high rate of hemolytic uremic syndrome. Also an unexpected high rate of coma and seizures leading to mechanical ventilation and ICU treatment was observed. MicroRNAs are small ribonucleotides orchestrating gene expression. We tested whether circulating microRNAs in serum of HUS patients during the 2011 epidemics are altered in this patient cohort and related to clinical manifestations. We profiled microRNAs using RNA isolated from serum of patients and healthy age-matched controls. The results were validated in 38 patients at baseline, 29 patients during follow-up and 21 age-matched healthy controls by miRNA-specific quantitative RT-PCR. Circulating levels of miR-24, miR-126 were increased in HUS patients versus controls. There was no association between these microRNAs and renal function or the need for renal replacement therapy. In contrast, levels of miR-126 were associated with neurological symptoms at baseline and during follow-up. In addition, miR-126 (on admission) and miR-24 (on admission and during follow-up) were associated with platelet count. Circulating microRNAs are strongly altered in this patient cohort and associated with neurological symptoms as well as platelet count.Keywords
This publication has 23 references indexed in Scilit:
- Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndromeJournal of Molecular and Cellular Cardiology, 2011
- Eculizumab in Severe Shiga-Toxin–Associated HUSNew England Journal of Medicine, 2011
- Circulating MicroRNAs as Biomarkers and Potential Paracrine Mediators of Cardiovascular DiseaseCirculation: Cardiovascular Genetics, 2010
- Pathophysiology of Typical Hemolytic Uremic SyndromeSeminars in Thrombosis and Hemostasis, 2010
- Delivery of MicroRNA-126 by Apoptotic Bodies Induces CXCL12-Dependent Vascular ProtectionScience Signaling, 2009
- Alternative Pathway of Complement in Children with Diarrhea-Associated Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2009
- Dicer is regulated by cellular stresses and interferonsMolecular Immunology, 2009
- Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosisProceedings of the National Academy of Sciences of the United States of America, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuriaNature Biotechnology, 2007